RGNX Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2016βFY2025
REGENXBIO Inc. had $170M of revenue in fiscal 2025, up 104.5% on the year before. Over five years, revenue changed +2.0% a year on average.
Last close Β· Oct 23, 2026
$6.68
6.8%Hi! I read REGENXBIO Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+104.5%
Yes. Sales grew 104.5% last year.
Does it make a profit?
β113.8%
No. It lost money last year.
Does profit turn into cash?
β74.1%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA Β· REGENXBIO Inc. had $170M of revenue in fiscal 2025, up 104.5% on the year before. Over five years, revenue changed +2.0% a year on average. Its operating margin was β94.6%, up 185.5Β pts: of every 100 in sales, about β95 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· REGENXBIO Inc. lost $194M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$126M in fiscal 2025, β74.1% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· In the last 12 months, insiders bought $0.9M and sold $0.9M of shares on the open market.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.9M
1 insider
Sold, 12 months
$0.9M
1 insider
Of sales under plans
100%
$0.9M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 27, 2026 | Gregory Austin CiongoliDirector | Bought | 53,407 | $9.36 | $0.5M | Form 4 |
| Aug 26, 2026 | Gregory Austin CiongoliDirector | Bought | 49,196 | $9.14 | $0.4M | Form 4 |
| Jul 2, 2026 | Steve PakolaChief Medical Officer | Sold plan | 2,161 | $13.64 | $0.0M | Form 4 |
| Jul 1, 2026 | Steve PakolaChief Medical Officer | Sold plan | 36,725 | $12.86 | $0.5M | Form 4 |
| Jun 29, 2026 | Steve PakolaChief Medical Officer | Sold plan | 19,608 | $11.04 | $0.2M | Form 4 |
| May 11, 2026 | Steve PakolaChief Medical Officer | Sold plan | 15,309 | $11.02 | $0.2M | Form 4 |
| Mar 10, 2026 | Steve PakolaChief Medical Officer | Sold plan | 5,124 | $10.35 | $0.1M | Form 4 |
| Oct 9, 2025 | Curran SimpsonChief Executive Officer, Director | Sold plan | 20,811 | $12.62 | $0.3M | Form 4 |
| Sep 29, 2025 | Curran SimpsonChief Executive Officer, Director | Sold plan | 7,624 | $10.03 | $0.1M | Form 4 |
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably REGENXBIO Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $457M | $365M | $275M | $235M | $230M |
| Interest coverage | 6.1x | β11.3x | β39.1x | β18.4x | β3.6x |
| Current ratio | 4.0x | 3.2x | 2.6x | 2.7x | 2.4x |
| Quick ratio | 4.0x | 3.2x | 2.6x | 2.7x | 2.4x |
| Total assets | $1.1B | $833M | $574M | $466M | $453M |
| Total liabilities | $350M | $317M | $262M | $206M | $350M |
| Shareholders' equity | $764M | $516M | $312M | $260M | $103M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· REGENXBIO Inc. passes 3 of 7 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 3 / 8 | 7 / 8 | 0 / 8 | 4 / 8 | 6 / 8 | 2 / 8 | 3 / 8 | 4 / 8 | 3 / 7 |
| Accruals ratio | β8.3% | β8.2% | β1.3% | 2.5% | β9.5% | β10.0% | β7.5% | β6.4% | β10.4% | β15.2% |
| Altman Z'' | 13.92 | 11.70 | 19.68 | 10.83 | 2.90 | 5.08 | 0.11 | β3.56 | β6.10 | β7.82 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $4.6M | $10.4M | $219M | $35.2M | $155M | $470M | $113M | $90.2M | $83.3M | $170M |
| Provision for credit losses | β | β | β | β | β | β | β | β | β$5.0M | β |
| Gross profit | $4.5M | $8.7M | $209M | $27.0M | $119M | $419M | $58.2M | $53.0M | $49.8M | β |
| Research and development | $45.5M | $57.2M | $83.9M | $124M | $166M | $181M | $242M | $232M | $209M | $228M |
| Operating income | β$65.3M | β$75.9M | $88.1M | β$149M | β$119M | $160M | β$263M | β$268M | β$233M | β$161M |
| Interest expense | β | β | β | β | $0.8M | $26.3M | $23.3M | $6.9M | $12.7M | $45.0M |
| Pretax income | β$63.4M | β$73.2M | $104M | β$97.5M | β$106M | $141M | β$280M | β$264M | β$227M | β$194M |
| Income tax | β$0.4M | $0.0M | $4.2M | β$2.8M | $5.2M | $13.4M | β$0.1M | β$0.2M | $0.0M | $0.0M |
| Net income | β$63.0M | β$73.2M | $99.9M | β$94.7M | β$111M | $128M | β$280M | β$263M | β$227M | β$194M |
| Net income to common | β$63.0M | β$73.2M | $99.9M | β$94.7M | β$111M | $128M | β$280M | β$263M | β | β |
| Diluted EPS | β$2.38 | β$2.45 | $2.73 | β$2.58 | β$2.98 | $2.91 | β$6.50 | β$6.02 | β$4.59 | β$3.76 |
| Diluted shares | 0.03B | 0.03B | 0.04B | 0.04B | 0.04B | 0.04B | 0.04B | 0.04B | 0.05B | 0.05B |
| Cash flow | ||||||||||
| Cash from operations | β$48.6M | β$58.0M | $105M | β$108M | β$54.1M | $219M | β$207M | β$218M | β$173M | β$124M |
| Capital expenditure | $8.1M | $7.2M | $13.3M | $11.7M | $26.9M | $84.2M | $30.7M | $10.0M | $2.4M | $2.4M |
| Free cash flow | β$56.7M | β$65.2M | $91.4M | β$119M | β$80.9M | $135M | β$238M | β$228M | β$176M | β$126M |
| Depreciation and amortization | $0.5M | $2.7M | $4.0M | $7.2M | $8.4M | $9.6M | $12.9M | $17.3M | $16.2M | $15.6M |
| Stock-based compensation | $7.0M | $10.6M | $16.6M | $26.9M | $31.9M | $38.8M | $40.8M | $40.3M | $38.5M | $34.6M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $89.6M | $161M | $320M | $296M | $476M | $457M | $365M | $275M | $235M | $230M |
| Current assets | $93.4M | $168M | $338M | $345M | $531M | $519M | $416M | $335M | $278M | $281M |
| Current liabilities | $9.7M | $14.4M | $22.2M | $33.7M | $81.4M | $130M | $130M | $130M | $103M | $118M |
| Property and equipment, net | $9.3M | $14.0M | $28.7M | $29.0M | $56.5M | $132M | $142M | $132M | $118M | $105M |
| Total assets | $173M | $199M | $544M | $498M | $708M | $1.1B | $833M | $574M | $466M | $453M |
| Total liabilities | $11.0M | $15.6M | $35.0M | $47.7M | $330M | $350M | $317M | $262M | $206M | $350M |
| Shareholders' equity | $162M | $183M | $509M | $450M | $378M | $764M | $516M | $312M | $260M | $103M |
| Margins | ||||||||||
| Gross margin | 97.9% | 83.6% | 95.6% | 76.6% | 76.9% | 89.0% | 51.6% | 58.8% | 59.7% | β |
| Operating margin | β1,423.8% | β730.2% | 40.3% | β422.9% | β77.1% | 34.0% | β233.2% | β297.1% | β280.0% | β94.6% |
| EBITDA margin | β1,412.0% | β704.3% | 42.1% | β402.6% | β71.7% | 36.0% | β221.8% | β277.9% | β260.6% | β85.4% |
| Net margin | β1,372.1% | β704.0% | 45.7% | β268.9% | β72.0% | 27.2% | β248.7% | β292.0% | β272.5% | β113.8% |
| FCF margin | β1,235.7% | β626.9% | 41.8% | β339.0% | β52.4% | 28.6% | β211.3% | β253.1% | β210.7% | β74.1% |
| Returns | ||||||||||
| Return on capital employed | β40.1% | β41.2% | 16.9% | β32.1% | β19.0% | 16.3% | β37.4% | β60.4% | β64.3% | β48.1% |
| Return on equity | β38.9% | β42.4% | 28.9% | β19.8% | β26.9% | 22.4% | β43.8% | β63.7% | β79.5% | β107.0% |
| Return on assets | β36.5% | β39.4% | 26.9% | β18.2% | β18.4% | 14.0% | β28.8% | β37.4% | β43.7% | β42.2% |
| Return on tangible equity | β38.9% | β40.0% | 19.6% | β21.0% | β29.5% | 16.7% | β54.3% | β84.5% | β87.5% | β188.7% |
| Growth | ||||||||||
| Revenue growth | β | 126.5% | 2,002.4% | β83.9% | 338.7% | 204.3% | β76.0% | β19.9% | β7.7% | 104.5% |
| Net income growth | β | β | β | β194.8% | β | β | β319.3% | β | β | β |
| EPS growth | β | β | β | β194.5% | β | β | β323.4% | β | β | β |
| FCF growth | β | β | β | β230.7% | β | β | β276.8% | β | β | β |
| Share count change | β | 13.1% | 22.7% | 0.1% | 1.6% | 17.8% | β1.7% | 1.3% | 13.2% | 4.2% |
| Financial health | ||||||||||
| Interest coverage | β | β | β | β | β154.6x | 6.1x | β11.3x | β39.1x | β18.4x | β3.6x |
| Current ratio | 9.7x | 11.6x | 15.2x | 10.2x | 6.5x | 4.0x | 3.2x | 2.6x | 2.7x | 2.4x |
| Quick ratio | 9.7x | 11.6x | 15.2x | 10.2x | 6.5x | 4.0x | 3.2x | 2.6x | 2.7x | 2.4x |
| Capital allocation | ||||||||||
| Capex / revenue | 177.6% | 68.9% | 6.1% | 33.3% | 17.4% | 17.9% | 27.3% | 11.0% | 2.9% | 1.4% |
| Stock comp / revenue | 153.2% | 102.0% | 7.6% | 76.2% | 20.7% | 8.3% | 36.2% | 44.6% | 46.2% | 20.3% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 3.0 | 7.0 | 0.0 | 4.0 | 6.0 | 2.0 | 3.0 | 4.0 | 3.0 |
| Altman Z'' | 13.9 | 11.7 | 19.7 | 10.8 | 2.9 | 5.1 | 0.1 | β3.6 | β6.1 | β7.8 |
| Accruals ratio | β8.3% | β8.2% | β1.3% | 2.5% | β9.5% | β10.0% | β7.5% | β6.4% | β10.4% | β15.2% |
Source: SEC EDGAR XBRL filings (CIK 0001590877). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
